Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.46 | N/A | +17.17% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.46 | N/A | +17.17% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management conveyed a positive outlook on the company's performance, particularly in terms of earnings. However, they did not provide specific guidance for future revenue.
Management expressed satisfaction with the EPS results despite the lack of revenue guidance.
They highlighted ongoing efforts to enhance product offerings and market reach.
The earnings report indicates that United Therapeutics performed well in terms of earnings per share, exceeding expectations by 17.17%. The stock reacted positively, rising 4.57%, likely driven by investor confidence in the company's profitability. However, the absence of revenue figures and future guidance leaves some uncertainty about overall growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PG&E CORP
Oct 29, 2012